Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp Corporate Call to Discuss the FDA Approval of AYVAKIT in Advanced SM Transcript

Jun 16, 2021 / 08:30PM GMT
Release Date Price: $85.56 (+1.53%)
Operator

Good afternoon. My name is Erica, and I will be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines Conference Call. (Operator Instructions)

Thank you. Kristin Hodous with Blueprint Medicines, you may begin your conference.

Kristin Hodous
Blueprint Medicines Corporation - Senior Manager of IR

Thank you, operator. Good morning, everyone, and welcome to Blueprint Medicines conference call to discuss the FDA approval of AYVAKIT in advanced SM. You can access the press release announcing the approval as well as the slides that we'll be reviewing today by going to the Investors & Media section of our website at www.blueprintmedicines.com.

With me on the call today are Jeff Albers, our Chief Executive Officer; Becker Hewes, our Chief Medical Officer; and Christy Rossi, our Chief Commercial Officer.

Before we get started, I would like to remind everyone that statements we make on this conference call will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot